- Home
- PMVP vs TCRX Comparison
PMVP vs TCRX Comparison
Compare PMVP & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | TCRX |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 63.6M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PMVP | TCRX |
|---|---|---|
| Price | $1.56 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $5.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 815.0K | 526.7K |
| Earning Date | 01-01-0001 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $69.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.82 | $0.88 |
| 52 Week High | $1.88 | $2.57 |
Technical Indicators
Market Signals| Indicator | PMVP | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 47.18 |
| Support Level | $1.32 | $0.92 |
| Resistance Level | $1.56 | $1.23 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 60.71 | 25.00 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.